Capricor Therapeutics Inc
NASDAQ:CAPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
US |
|
P
|
Pernod Ricard SA
F:PER
|
FR |
|
Fugro NV
F:F3DC
|
NL |
|
C
|
Credit Agricole SA
XHAM:XCA
|
FR |
|
Woori Financial Group Inc
F:2WGA
|
KR |
|
DeNA Co Ltd
F:D2N
|
JP |
|
China High Speed Transmission Equipment Group Co Ltd
F:BGR
|
KY |
|
S
|
STAAR Surgical Co
F:SR3
|
US |
|
P
|
PriceSmart Inc
F:PS8
|
US |
Intrinsic Value
Is CAPR undervalued or overvalued?
See the intrinsic value estimate for Capricor Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
CAPR looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with CAPR’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Capricor Therapeutics Does
Capricor Therapeutics is a biotechnology company that develops cell-based medicines for serious diseases, with a main focus on heart and muscle disorders. Its lead program is deramiocel, an allogeneic cardiosphere-derived cell therapy being studied for Duchenne muscular dystrophy, a genetic disease that weakens muscles over time. The company also works on exosome-based therapies, which use tiny particles released by cells as a way to deliver treatment signals.
- Headquarters
- United States of America US
- Employees
- 231
- IPO date
- Jun 4, 2002
Capricor Therapeutics has no economic moat
Capricor Therapeutics Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Capricor Therapeutics Inc
Earnings Waterfall
Capricor Therapeutics Inc
The intrinsic value for Capricor Therapeutics Inc (CAPR) under the Base Case is hidden USD.
Compared with the current market price of 5.73 USD, the stock appears hidden.